- Home
- FHN vs LEGN Comparison
FHN vs LEGN Comparison
Compare FHN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FHN | LEGN |
|---|---|---|
| Founded | 1864 | 2014 |
| Country | United States | United States |
| Employees | 7300 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FHN | LEGN |
|---|---|---|
| Price | $23.49 | $17.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 14 |
| Target Price | $25.76 | ★ $63.46 |
| AVG Volume (30 Days) | ★ 6.0M | 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.54 | $67.72 |
| Revenue Next Year | $4.19 | $43.82 |
| P/E Ratio | $13.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.23 | $16.24 |
| 52 Week High | $26.56 | $45.30 |
Technical Indicators
Market Signals| Indicator | FHN | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.41 | 41.00 |
| Support Level | $22.02 | $16.24 |
| Resistance Level | $25.07 | $23.68 |
| Average True Range (ATR) | 0.79 | 0.88 |
| MACD | -0.19 | 0.18 |
| Stochastic Oscillator | 16.03 | 8.09 |
Price Performance
Historical ComparisonAbout FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.